Mutations in methylenetetrahydrofolate reductase or cystathionine β‐syntase gene, or a high‐methionine diet, increase homocysteine thiolactone levels in humans and mice
- 27 February 2007
- journal article
- Published by Wiley in The FASEB Journal
- Vol. 21 (8), 1707-1713
- https://doi.org/10.1096/fj.06-7435com
Abstract
Genetic disorders of homocysteine (Hcy) metabolism or a high-methionine diet lead to elevations of plasma Hcy levels. In humans, severe genetic hyperhomocysteinemia results in premature death from vascular complications whereas dietary hyperhomocysteinemia is often used to induce atherosclerosis in animal models. Hcy is mistakenly selected in place of methionine by methionyl-tRNA synthetase during protein biosynthesis, which results in the formation of Hcy-thiolactone and initiates a pathophysiological pathway that has been implicated in human vascular disease. However, whether genetic deficiencies in Hcy metabolism or a high-methionine diet affect Hcy-thiolactone levels in mammals has been unknown. Here we show that plasma Hcy-thiolactone is elevated 59-fold and 72-fold in human patients with hyperhomocysteinemia secondary to mutations in methylenetetrahydrofolate reductase and cystathionine beta-synthase genes, respectively. We also show that mice, like humans, eliminate Hcy-thiolactone by urinary excretion; in contrast to humans, however, mice also eliminate significant amounts of plasma total Hcy (approximately 38%) by urinary excretion. In mice, hyperhomocysteinemia secondary to a high-methionine diet leads to 3.7-fold and 25-fold increases in plasma and urinary Hcy-thiolactone levels, respectively. Thus, we conclude that hyperhomocysteinemia leads to significant increases in the atherogenic metabolite Hcy-thiolactone in humans and mice.Keywords
Funding Information
- American Heart Association
- National Science Foundation
This publication has 41 references indexed in Scilit:
- Pathophysiological Consequences of Homocysteine ExcessJournal of Nutrition, 2006
- Homocysteine Lowering with Folic Acid and B Vitamins in Vascular DiseaseThe New England Journal of Medicine, 2006
- Homocysteine Trials — Clear Outcomes for Complex ReasonsThe New England Journal of Medicine, 2006
- Vitamin Intervention for Stroke Prevention TrialStroke, 2005
- Mechanisms of homocysteine‐induced atherothrombosisJournal of Thrombosis and Haemostasis, 2005
- Homocysteine, MTHFR and risk of venous thrombosis: a meta‐analysis of published epidemiological studiesJournal of Thrombosis and Haemostasis, 2005
- Molecular basis of homocysteine toxicity in humansCellular and Molecular Life Sciences, 2004
- Plasma Homocysteine as a Risk Factor for Dementia and Alzheimer's DiseaseThe New England Journal of Medicine, 2002
- Vascular Outcome in Patients With Homocystinuria due to Cystathionine β-Synthase Deficiency Treated ChronicallyArteriosclerosis, Thrombosis, and Vascular Biology, 2001
- Homocysteine Induces Programmed Cell Death in Human Vascular Endothelial Cells through Activation of the Unfolded Protein ResponseOnline Journal of Public Health Informatics, 2001